Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 9/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714372 | 0.86 | HSD17B10 (0.65) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL29745613 | 0.86 | HSD17B10 (0.65) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL30701985 | 0.82 | CYP3A4 (0.40) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL20045407 | 0.82 | CYP3A4 (0.68) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL22112026 | 0.82 | CYP3A4 (0.40) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL3155200 | 0.77 | CYP3A4 (0.50) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL20132899 | 0.77 | ALOX15 (0.42) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL1156272 | 0.75 | HSD17B10 (0.50) | HSD17B10HPGDCYP3A4CRHBPCRHR2 | |
| SCHEMBL12917725 | 0.75 | ESR1 (0.56) | CYP3A4ESR1ESR2 | |
| SCHEMBL30225848 | 0.75 | HSD17B10 (0.50) | HSD17B10HPGDCYP3A4CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12421193-B2 | GPR52 modulators and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| US-12258338-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2025-03-25 | — | — | US | disclosed |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4139284-A1 | GPR52 MODULATORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220227747-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC (UK) LIMITED (GB) | 2022-07-21 | — | — | US | disclosed |
| WO-2021216705-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216705-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-2098583-A2 | Optically isotropic liquid crystal medium and optical device | Chisso Corporation (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20090135368-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090135368-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090135368-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1650285-B1 | Liquid crystal composition containing an optically active compound and liquid crystal electro-optical element | SEIMI CHEM KK (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-0637623-B1 | Cyclic hydrocarbon derivative and liquid crystal composition containing the same | DAINIPPON INK & CHEMICALS (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-5536443-A | DUTERIUM CONTAINING COMPOUNDS FOOR ELECTROOPTICAL APPARATUS | DAINIPPON INK & CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5474707-A | Electrooptic display | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-12-12 | — | — | US | disclosed |
| EP-0637623-A1 | Cyclic hydrocarbon derivative and liquid crystal composition containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-02-08 | — | — | EP | disclosed |
| US-4060562-A | SULFUR CONTAINING CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258338-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, CRH | HSD17B10 1698/4885HPGD 2475/4885CYP3A4 239/4885 |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | HSD17B10 1698/4885HPGD 2475/4885CYP3A4 239/4885 |
| US-20220227747-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | HSD17B10 1698/4885HPGD 2475/4885CYP3A4 239/4885 |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | HSD17B10 1107/4885HPGD 979/4885CYP3A4 2659/4885 |
| US-12421193-B2 | GPR52 modulators and methods of use | GPR52, GPR68, GPR35 | HSD17B10 1107/4885HPGD 979/4885CYP3A4 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.